Sagimet reports 52-week Phase 3 open-label extension data showing 56.7% IGA success for denifanstat in moderate to severe acne

• Sagimet Biosciences reported positive 52-week results from Ascletis’ Phase 3 open-label extension trial of denifanstat in moderate to severe acne.
• Findings were already presented at the European Academy of Dermatology and Venereology Congress in Vienna.
• Patients showed sustained improvement across key clinical measures over long-term dosing, including those who switched from placebo.
• Tolerability supported extended use, with no adverse event-related permanent discontinuations reported.
• U.S. patient screening for Sagimet’s AURORA Phase 3 trial is expected to start in October 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300600PRIMZONEFULLFEED9836645) on September 30, 2026, and is solely responsible for the information contained therein.